紫杉醇联合卡铂治疗晚期非小细胞肺癌

目的 评价紫杉醇加卡铂联合化疗对晚期非小细胞肺癌(NSCLC)病人的疗效及毒副作用。方法 紫杉醇每次剂量175／m2，3h静脉滴注，于第1天给药。在紫杉醇化疗前给予地塞米松、苯海拉明和西咪替丁预防过敏反应。卡铂每次剂量300mg／m2，1h静脉滴注，于第1天给药。化疗周期每3周重复。结果 共86例病人接受2～7个疗程的化疗。总缓解率为49％，5例(6％)完全缓解，37例(43％)部分缓解，35例(41％)肿瘤稳定，9例(10％)肿瘤发展。中位缓解期7个月，全组中位生存期11个月。本方案化疗所致的毒性反应主要为骨髓抑制肌肉关节痛手足感觉异常和脱发，通常为轻度反应(1度或2度反应)。结论 紫杉醇加卡铂是治疗晚期NSCLC有效的联合化疗方案，其毒性反应容易耐受，该方案值得进一步临床研究。

Paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of paclitaxel combined with carboplatin chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods,Paclitaxel was administered by 3 hour introvenous infusion at a dose of 175 nag/m2 on day 1.Dexamethasone,diphenhydramine and cimetidine were given before paclitaxd to prevent allergic reactions.Carboplatin Was given byl hourintravenousinfusion at a dose of 300mg/m2on dayl.Chemotherapy cycleswere repeated every3 weeks.Results A total of 86 patients received 2 to 7 cycles of chemotherapy.The overall response rate Was 49%,with 5(6%)complete responses and 37(43%)partial responses.The disease was stable in 35 patients(41%)and was progressive in 9 patients(10%).The median duration of response was 7 months and the median overall survival time Was 11 months.The major toxic reactions associated with this chemotherapy regimen were myelosuppression,myalgias/arthralgia,peripheral neuropathy,and alopecia;but they were generally mild (grade 1 or 2).Conclusion The paclitaxel-carboplatin chemotherapy regimen is an effective method with tolerable toxcity in advanced NSCLC and deserves further dinical investigation.